Browse the evidence

Metformin treatment alters gut microbiota composition (increasing Escherichia coli and decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.

If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fatty acids. This is a key part of how the drug works, though it can cause temporary stomach upset for some people.

A 20-minute theory-informed documentary presenting health, environmental, and animal welfare arguments does not significantly reduce actual meat and animal product (MAP) consumption over a 12-day period when social desirability bias is minimized.

Watching a documentary about the benefits of reducing meat consumption is unlikely to change your actual eating habits within two weeks, even if it makes you want to try. The study shows that while people might *say* they will eat less meat (especially if they think the researchers want them to), their actual consumption remains unchanged. To make a real change, information alone is insufficient; you need concrete plans, recipes, and environmental support, not just emotional appeals.

GLP-1 receptor agonists lower serum TSH levels in patients with Type 2 Diabetes, particularly those who experience weight loss, without necessarily changing free thyroxine (FT4) levels, suggesting a mechanism involving central nervous system GLP-1 receptors or improved thyroid hormone sensitivity.

If your TSH levels drop while on a GLP-1 medication, it is likely due to your weight loss or improved metabolic sensitivity, not necessarily a thyroid problem. Your doctor will likely check your Free T4 to ensure your thyroid function is normal. This change is generally considered a positive metabolic adaptation rather than a disease state.

The peptide drug GUB021794, a GLP-1 receptor agonist derived from a secretin backbone, promotes dose-dependent body weight loss in diet-induced obese mice comparable to the clinically approved drug semaglutide.

This research identifies a new peptide drug, GUB021794, which mimics the hormone GLP-1 to reduce appetite and body weight. In obese mice, it worked as well as the popular drug semaglutide but was designed to last longer in the body, allowing for once-weekly dosing instead of daily. This suggests a potential future treatment option for obesity that offers similar weight loss benefits with less frequent administration.

Adults with diabetes and overweight/obesity are significantly more likely to use weight-inducing (WI) medications than weight-reducing (WR) medications, with WI use being 4 to 20 times higher than WR use, despite clinical guidelines recommending preferential use of WR agents.

If you have diabetes and are overweight, your current medication might be working against your weight loss goals. Many common diabetes drugs cause weight gain. Ask your doctor about switching to weight-reducing options like GLP-1 agonists or SGLT2 inhibitors, which are now recommended for people with your profile. Be aware that these drugs can be expensive and may require injections, but they are designed to help you lose weight, unlike older medications.

Spirulina supplementation does NOT significantly preserve skeletal muscle mass (SMM) during gradual weight loss compared to placebo; both groups lost similar amounts of muscle mass.

Do not rely on spirulina to preserve your muscle mass during a weight cut. This study showed that wrestlers taking spirulina lost the same amount of muscle as those taking a placebo. To preserve muscle, you must ensure your overall protein intake is high (1.6-3.1 g/kg/day) in addition to following your gradual weight loss diet.

High body mass index (BMI) is a strong independent risk factor for the development of chronic kidney disease (CKD) and end-stage renal disease (ESRD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to prevent kidney disease. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. Focus on sustainable lifestyle changes like proper nutrition and exercise to lower your BMI, especially if you have high blood pressure or diabetes.

High BMI acts as a direct risk factor for chronic kidney disease (CKD) through compensatory renal hyperfiltration and increased intraglomerular pressure, independent of diabetes or hypertension.

Maintaining a healthy weight is critical for kidney health. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. This damage happens even if you don't have diabetes or high blood pressure. Weight management through lifestyle changes is the primary way to prevent this specific type of kidney injury.

High cost or insurance-related barriers are the primary drivers of discontinuation for obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice, accounting for nearly half of all early and late discontinuations.

If you are stopping semaglutide or tirzepatide, the most likely reason is cost or insurance issues, not that the drug didn't work. Check your insurance coverage, look for manufacturer coupons, and talk to your doctor about financial assistance programs before assuming the treatment is unsuitable for you.

Long-term use of GLP-1 receptor agonists (≥78 weeks) significantly increases the risk of deep vein thrombosis (DVT) compared to placebo or other anti-diabetic drugs.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza) for more than a year, be aware that your risk of deep vein thrombosis (DVT) is higher than if you were not taking it. This risk is most notable in people with existing cardiovascular disease. However, the absolute increase in risk is small. Discuss any history of blood clots with your doctor before starting or continuing long-term therapy.

Overall Venous Thromboembolism (VTE) risk is not significantly increased by GLP-1RA use, as the increase in DVT is offset by no change in Pulmonary Embolism (PE) risk.

Taking GLP-1 medications does not significantly increase your overall risk of blood clots (VTE) when looking at the big picture. While there is a small, non-significant upward trend, it is not statistically proven to be dangerous for the general population. The specific risk of DVT is only significant with very long-term use.

BMI is an inadequate and potentially harmful sole metric for assessing obesity severity and treatment response.

Do not rely on BMI alone. Your health is determined by your metabolic markers and fat distribution, not just your weight. Seek a comprehensive assessment that looks at your overall health risks.

Global average total protein intake (78.2 g/day) exceeds the minimum requirement for health in all surveyed countries, with national means never falling below 46 g/day, indicating that protein deficiency is not a widespread global issue in terms of quantity.

You do not need to worry about global protein shortages or your personal intake being critically low if you eat a standard diet. The global average is 78g/day, and even the lowest-consuming nations average 46g/day, which is sufficient. Focus on the source (animal vs. plant) and overall diet quality rather than fearing protein deficiency.

GLP-1 medicines for obesity are predominantly tested in white/Caucasian populations (79%) with significant under-representation of non-white, Black, Asian, and Indigenous groups compared to their prevalence in multiethnic national populations.

Current GLP-1 obesity trials heavily feature white participants (79%). If you belong to a racial or ethnic minority, be aware that the standard dosing and efficacy data may not fully reflect your specific physiological response or risk profile. Advocating for or seeking out diverse clinical data is important for personalized care.

GLP-1 obesity trials are geographically concentrated in high-income countries (84.2% of sites), contrasting with the global prevalence of obesity which is highest in low- and middle-income countries (LMICs).

Most GLP-1 trials were conducted in high-income countries, yet most people with obesity live in low- and middle-income countries. This geographic gap means that treatment guidelines and availability may not reflect the needs of the majority of the global population.

SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.

If you have Type 2 Diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively protect your heart and kidneys by reducing inflammation and oxidative stress, which are major drivers of heart disease in diabetic patients.

GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.

GLP-1 agonists may help prevent blood clots by making platelets less sticky, which adds to their heart-protective benefits beyond just sugar control.

Intestinal deficiency of Acyl-CoA synthetase 5 (ACSL5) reduces food intake and protects against diet-induced obesity by increasing postprandial secretion of GLP-1 and PYY.

This research suggests that how your body processes dietary fat in the intestine—specifically through the enzyme ACSL5—can influence your hunger hormones (GLP-1 and PYY). When this process is altered, it can lead to increased feelings of fullness and reduced food intake, potentially protecting against weight gain on high-fat diets. While this is a genetic mechanism in mice, it highlights the importance of gut hormones in regulating appetite and energy balance.

Semaglutide (2.4 mg weekly) induces MASH resolution in patients with stage 2-3 fibrosis, though it does not significantly improve fibrosis itself.

Semaglutide 2.4 mg weekly is highly effective at resolving active liver inflammation (MASH) in patients with moderate fibrosis. However, it does not reverse the scarring (fibrosis) itself. Patients should expect significant weight loss and metabolic improvement, but should not assume their liver scarring will disappear with this drug alone.

Statins reduce the risk of developing MASLD and progression to liver fibrosis, and may reduce cardiovascular events in MASLD patients, despite not directly reducing liver fat.

If you have fatty liver and high cardiovascular risk, you should take statins. They do not remove liver fat, but they reduce inflammation and fibrosis, and significantly lower your risk of heart attacks and strokes. The benefits outweigh the theoretical risks.

Pioglitazone improves MASH resolution and may improve fibrosis, but is limited by side effects like weight gain and heart failure exacerbation.

Pioglitazone can resolve MASH and improve fibrosis, but it causes weight gain and fluid retention, which can worsen heart failure. It is not a first-line treatment but may be considered if other options fail and heart failure is not a concern.

Once-weekly semaglutide treatment is associated with a significant increase in pulse rate compared to once-daily sitagliptin.

If you take semaglutide, expect your resting heart rate to increase slightly (by about 3 beats per minute) compared to if you took sitagliptin. This is a known side effect. While usually not dangerous, it is worth monitoring, especially if you have underlying heart conditions.

Semaglutide treatment is associated with a higher risk of total adverse events and premature treatment discontinuation compared to sitagliptin, although the risk of serious adverse events is not significantly different.

Be prepared for a higher likelihood of side effects and stopping the medication early when starting semaglutide compared to sitagliptin. Most side effects are gastrointestinal. Slow dose escalation can help. However, serious adverse events are not significantly more common with semaglutide.

Rapid and substantial weight reduction, such as that achieved by bariatric surgery or certain medications, may result in greater reductions in lean muscle mass compared to gradual weight reduction.

If you are undergoing rapid weight loss (e.g., surgery or strong medications), prioritize resistance training and adequate protein intake to protect your muscle mass. Monitor your body composition, not just scale weight, to ensure you are losing fat, not muscle.